Lataa...
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a fatal disease with rising incidence in the world. For advanced HCC, sorafenib, a multikinase inhibitor, is the only systemic therapy with proven survival benefits. Sorafenib is a pan-VEGF receptor inhibitor, and thus many studies have focused its antivascular effe...
Tallennettuna:
| Julkaisussa: | Immunotherapy |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Future Medicine Ltd
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5619018/ https://ncbi.nlm.nih.gov/pubmed/26865127 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt.15.126 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|